On 12 October 2026 a Supreme Court bench of Justices Vikram Nath and Sandeep Mehta asked why the Centre's 30%-of-MRP trade-margin cap was limited to non-scheduled anti-cancer medicines
The Centre told the Court the cancer-drug cap would save patients about Rs 2,500 crore a year; the bench asked it to submit modalities for wider price regulation by 27 October 2026
Examples cited: a saline drip line costing the retailer Rs 11 but sold at about Rs 270, and an Indian-made cardiac stent at about Rs 5,000 against hospital prices above Rs 25,000
Solicitor General Tushar Mehta argued margins fund supply to remote areas; the Court said keeping price-controlled medicines available is the government's responsibility
Lets the Centre control production, supply and distribution of essential commodities; every Drugs (Prices Control) Order is issued under it
Ceiling prices for Schedule I (NLEM) formulations = simple average price to retailer of brands with at least 1% market share + 16% retailer margin. Non-scheduled drugs may raise MRP by at most 10% a year. Paragraph 19 allows price-fixing in extraordinary circumstances - the route for the February 2019 cap on 42 anti-cancer drugs
384 medicines, issued by the Ministry of Health and Family Welfare; inclusion makes a drug 'scheduled' and price-controlled
The Supreme Court has read the right to health into the right to life - the basis on which affordability of medicines reaches the Court
Set up on 29 August 1997; fixes ceiling prices, enforces DPCO 2013 and recovers overcharging; approved the 30% cancer-drug margin cap
Department in the Ministry of Chemicals and Fertilizers since 2008; NPPA is its attached office
Trade margins capped at 30% for 42 non-scheduled anti-cancer drugs under Paragraph 19
Supreme Court floats a uniform 16% margin for all medicines
NPPA approves 30% margin cap on non-scheduled anti-cancer medicines
Court questions limiting the cap to cancer drugs
Next hearing; Centre's modalities due
GS Paper II > Health; Government policies and interventions; Judiciary
General Awareness > Polity > Regulatory bodies
The power of the Supreme Court of India to decide disputes between the Centre and the States falls under its
Answer: original jurisdiction
With reference to the Constitution of India, consider the following statements: 1. No High Court shall have the jurisdiction to declare any central law to be constitutionally invalid. 2. An amendment to the Constitution of India cannot be called into question by the Supreme Court of India. Which of the statements given above is/are correct?
Answer: Neither 1 nor 2
Who/Which of the following is the custodian of the Constitution of India?
Answer: The Supreme Court of India
In India, Judicial Review implies
Answer: the power of the Judiciary to pronounce upon the constitutionality of laws and executive orders.
With reference to the Constitution of India, prohibitions or limitations or provisions contained in ordinary laws cannot act as prohibitions or limitations on the constitutional powers under Article 142. It could mean which one of the following?
Answer: The Supreme Court of India is not constrained in the exercise of its powers by laws made by the Parliament.
Difference between the price at which the first point of sale (stockist) buys and the MRP the patient pays
A medicine in Schedule I of DPCO 2013 (the NLEM), subject to a ceiling price
Price at which a retailer buys; the DPCO ceiling adds a 16% margin to its average